Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Exclusion criteria

• . No clinical abnormalities noted in the12-lead electrocardiogram in the opinion of the investigator (Refer also to exclusion criterion 13).
• . No evidence of macular edema in an ophthalmology evaluation (performed by an ophthalmologist), supported with optical coherence tomography, where available (dependent on site capability) at screening.
• . Eligible male and female participants must agree not to participate in a conception process (i.e. active attempt to let female partner to become pregnant or to impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30 days after the last dose of study drug.
• . Clinically significant infection as judged by the investigator with an end date less than 6-weeks prior to treatment start (Day 1). In case of infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection, this infection must have ended at least 8 weeks prior to Day 1.
• . Infection with hepatitis C virus anytime in the past; confirmed active infection with hepatitis B virus at screening.
• . History of severe renal or severe hepatic impairment.
• . Current active or latent tuberculosis (TB).
• . A positive diagnostic TB test at screening.